A Phase 4 interventional study of Vaxigrip Tetra Sanofi Pasteur Europe in Diabetes Mellitus, Type 1, sponsored by Aarhus University Hospital. Recruiting at 10 sites in Denmark. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Aarhus University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 46th largest by planned enrollment of the 157 interventional ones that give a count, is one of 7 that started in 2022, is one of 19 in phase 4, reaches primary completion later than 17 of the 34 other live ones, and was the 154th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 2–18
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Klavs Würgler Hansen · Sites in Denmark
Ages 18+
Henrik Bo Wiberg Larsson · Sites in Denmark, Germany
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 34 · Phase 4 19
First in 1995; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 157 interventional studies, 175 across the 38 observational. Of the 147 that completed or were terminated, 28 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 196 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 1 with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07247734Asger Lund, MDThe Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | 2026-12-22 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
Add all 11 to your calendar (.ics) → With an account.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In a multicenter, prospective, randomized, controlled clinical trial to compare influenza vaccination and placebo in sustaining β cell function in early type 1 diabetes mellitus.
Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the insulin-producing β cells in the pancreatic islets. In theory, immunotherapies aimed at re-programming the immune system to avoid β cell destruction is a promising strategy to prevent T1D or delay onset of overt disease.
In this trial we test the hypothesis that influenza vaccination is superior to no influenza vaccination in sustaining β cell function in early T1D. Secondary outcome measures include change in autoantibodies directed against antigens present in the pancreatic islets, measures of severity of disease, change in inflammatory markers, and antibody titers against the four viruses included in the vaccine.
Despite improvements in care, T1D is a leading cause of debilitating complications and early death globally. Children with residual β cell function are at lower risk for severe hypoglycemia, have better diabetes regulation, and have lower insulin requirements compared to children without residual β cell function. Thus, a simple, cheap treatment to mitigate T1D is highly warranted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Influenza vaccine, 0.5 mL.
Biological: Vaxigrip Tetra Sanofi Pasteur Europe
Placebo, 0.5 mL saline.
Biological: Vaxigrip Tetra Sanofi Pasteur Europe
We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
Change in fasting residual β cell (C-peptide) function.
Measured as the area under the concentration-time curve (AUC) for mixed-meal tolerance test-stimulated C-peptide concentration over 4 hours relative to baseline (AUC 0-4 h, C-peptide, 12 months/ AUC 0-4 h, C-peptide, baseline)
Time frame: 12 months
Change in fasting residual β cell (C-peptide) function.
Measured as the area under the concentration-time curve (AUC) for mixed-meal tolerance test-stimulated C-peptide concentration over 4 hours relative to baseline (AUC 0-4 h, C-peptide, 6 months/ AUC 0-4 h, C-peptide, baseline)
Time frame: 6 months.
Change in HbA1c
Measured as standard laboratory test in mmol/mol
Time frame: 12 months.
Change in insulin requirements.
Measured as total insulin dose per kg body weight per day as a mean for the last 14 days.
Time frame: 12 months.
Time-In-Range of blood glucose.
Defined as percentage time in range (3.9-10.0 mmol/L) of continuous glucose monitoring over 14 days.
Time frame: 12 months.
Variation of blood glucose.
Determined as percent coefficient of variation of blood glucose over 14 days.
Time frame: 12 months.
Proportion of participants with stimulated C-peptide >0.2 pmol/mL
Proportion of participants in each of the treatment groups with stimulated C-peptide \>0.2 pmol/mL
Time frame: 12 months
HbA1c time in range
Defined as percentage time in range (48mmol/mol or below)
Time frame: 12 months.
Insulin Dose Adjusted A1c
Defined as: IDAA1c = HbA1c (%) +4\*total daily insulin dose (IE/kg/24 h)
Time frame: 12 months
Variation of blood glucose.
Determined as percent coefficient of variation of blood glucose over 14 days.
Time frame: 6 months.
Change in GAD 65 antibodies.
Laboratory method to be determined
Time frame: 12 months.
Change in GAD 65 antibodies.
Laboratory method to be determined.
Time frame: 6 months.
Change in regulatory T cells.
Defined as percentage change.
Time frame: 12 months.
Change in insulin autoantibodies.
Laboratory method to be determined.
Time frame: 12 months.
Change in zinc transporter-8 autoantibodies
Laboratory method to be determined.
Time frame: 12 months.
Change in islet cell autoantibodies.
Laboratory method to be determined.
Time frame: 12 months.
Change in cytokine levels.
Markers to be determined: IL2, IL6, IL8, IL10, TNFα. Laboratory method to be determined.
Time frame: 12 months.
Change in cytokine levels.
Markers to be determined: IL2, IL6, IL8, IL10, TNFα. Laboratory method to be determined.
Time frame: 6 months.
Unplanned hospitalizations.
Number of unplanned hospitalizations with reasons for hospitalizations.
Time frame: 12 months.
Serum hemagglutinin inhibition antibody titers against the four viruses included in the vaccine
Antibody titers.
Time frame: 12 months.
Serum hemagglutinin inhibition antibody titers against the four viruses included in the vaccine
Antibody titers.
Time frame: 6 months.
Clnical endpoints.
Hospitalizations and unplanned hospital contacts.
Time frame: Up to 5 years.
Treatment-emergent hypoglycemic events (safety outcome)
Hypoglycemic events reported according to the American Diabetes Association classification
Time frame: Up to 12 months.
Treatment-emergent events of diabetic ketoacidosis (safety outcome)
Events of diabetic ketoacidosis.
Time frame: Up to 12 months.
Started Dec 2022 (actual). Primary completion is estimated for May 2027, 52 months after the start.
Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 52 months is above that.
Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion May 2026 → May 2027 and completion May 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.